0000000000270381

AUTHOR

F. Di Raimondo

showing 8 related works from this author

Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma

2013

Abstract Background A combination of bortezomib (1.3 mg/m2), melphalan (5 mg/m2), and dexamethasone (40 mg) (BMD), with all three drugs given as a contemporary intravenous administration, was retrospectively evaluated. Patients and methods Fifty previously treated (median 2 previous lines) patients with myeloma (33 relapsed and 17 refractory) were assessed. The first 19 patients were treated with a twice-a-week (days 1, 4, 8, 11, ‘base’ schedule) administration while, in the remaining 31 patients, the three drugs were administered once a week (days 1, 8, 15, 22, ‘weekly’ schedule). Results Side-effects were predictable and manageable, with prominent haematological toxicity, and a better tox…

AdultMaleMelphalanmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsSalvage therapyGastroenterologyDexamethasoneDisease-Free SurvivalDrug Administration ScheduleBortezomibRefractoryRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalMelphalanMultiple myelomaDexamethasoneAgedRetrospective StudiesAged 80 and overBortezomibbusiness.industryHematologyMiddle Agedmedicine.diseaseBoronic AcidsRegimenTreatment OutcomeOncologyPyrazinesInjections IntravenousFemaleMultiple MyelomabusinessFollow-Up Studiesmedicine.drug
researchProduct

Differences among young adults, adults and elderly chronic myeloid leukemia patients

2014

Abstract BACKGROUND: The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear how the characteristics of the disease vary with age. In children, where CML is very rare, it presents with more aggressive features, including huge splenomegaly, higher cell count and higher blast cell percentage. PATIENTS AND METHODS: To investigate if after childhood the disease maintains or loses these characteristics of aggressiveness, we analyzed 2784 adult patients, at least 18 years old, registered by GIMEMA CML WP over a 40-year period. RESULTS: Young adults (YAs: 18-29 years old) significantly differed from adults (30-59 years old) and elderly patients (at least 60 years old)…

MalePediatricsHost responseBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young Adult; Oncology; HematologyTyrosine kinase inhibitorDiseaseAntineoplastic AgentTyrosin kinase inhibitorProtein-Tyrosine Kinasehemic and lymphatic diseases80 and overAge FactorProspective StudiesYoung adultChronicBCR-ABLAged 80 and overLeukemiaIncidence (epidemiology)Chronic myeloid leukemiaAge FactorsMyeloid leukemiaHematologyMiddle AgedProtein-Tyrosine KinasesPrognosisLeukemiaOncologybcr-abl1FemaleBCR-ABL; chronic myeloid leukemia; prognosis; tyrosine kinase inhibitors; young adultsHumanAdultyoung adultsmedicine.medical_specialtyPrognosiProtein Kinase InhibitorAntineoplastic Agentschronic myeloid leukemia; bcr-abl1; Tyrosin kinase inhibitor; prognosis; young adultsNOYoung Adultchronic myeloid leukemiaLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young AdultProtein Kinase InhibitorsAgedTyrosine kinase inhibitorsAdult patientsbusiness.industrymedicine.diseaseClinical trialBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young Adult; Hematology; OncologyProspective StudieBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young Adult; Medicine (all); Hematology; OncologyImmunologySplenomegalyBCR-ABL PositiveBCR-ABL chronic myeloid leukemia prognosis tyrosine kinase inhibitors young adultsprognosisbusinessSpleenYoung adultsMyelogenous
researchProduct

Clinical and endoscopic presentation of primary gastric lymphoma: a multicentre study

2006

1. Aliment Pharmacol Ther. 2006 Mar 15;23(6):721-6. Clinical and endoscopic presentation of primary gastric lymphoma: a multicentre study. Andriani A, Zullo A, Di Raimondo F, Patti C, Tedeschi L, Recine U, Caruso L, Bonanno G, Chiarenza A, Lizzani G, Miedico A, Romanelli A, Costa A, Linea C, Marrone C, Mirto S, Mistretta A, Montalbano L, Restivo G, Vinci M, Bibas M, Hassan C, Stella F, Cottone M, Morini S. Department of Haematology and Gastroenterology, 'San Giacomo' and 'Nuovo Regina Margherita' Hospitals, Rome, Italy. BACKGROUND: Although the stomach is the most frequent site of intestinal lymphomas, few data are available on both clinical endoscopic presentation of gastric lymphoma and p…

Malegastric lymphoma.helicobactermedicine.medical_specialtyLymphomaSettore MED/12 - GASTROENTEROLOGIAGastroenterologyEndoscopy GastrointestinalHelicobacter Infectionsimmune system diseasesStomach Neoplasmshemic and lymphatic diseasesInternal medicinemedicineGastric mucosaHumansPharmacology (medical)AntrumNeoplasm StagingRetrospective StudiesHepatologymedicine.diagnostic_testbiologyHelicobacter pyloribusiness.industryGastric lymphomaStomachStomachGastroenterologyRetrospective cohort studyHelicobacter pyloriMiddle Agedmedicine.diseasebiology.organism_classificationEndoscopyLymphomamedicine.anatomical_structureGastric MucosaFemalebusiness
researchProduct

Theoretical and experimental study of the kinetics of particle chains near electrodes in dielectrophoretic devices

2014

Using a three dimensional coupled Monte Carlo-Poisson algorithm and experimental results we studied the role of the particle-particle dipole interaction on the kinetics of a system of human cells suspended in a static liquid medium under the action of an oscillating non-uniform electric field generated by polynomial electrodes. We found that the kinetics of the cells during negative/repulsive dielectrophoresis depends on the local distribution of particles. If the cells have generated long chains during positive/attractive dielectrophoresis, such chains can hinder subsequent detachment resulting in a reduction of the separation/manipulation efficiency of dielectrophoretic device. This effec…

Materials sciencekinetics of particle chains dielectrophoretic devicesparticle chainsKineticsElectrodeDielectrophoresisAnalytical chemistrycellsParticle chainsNanotechnologyDielectrophoresis
researchProduct

Phylogenetic analysis in the clinical risk management of an outbreak of hepatitis C virus infection among transfused thalassaemia patients in Italy

2021

Background: Occurrence of hepatitis C virus (HCV) infection is reduced by effective risk management procedures, but patient-to-patient transmission continues to be reported in healthcare settings. Aim: To report the use of phylogenetic analysis in the clinical risk management of an HCV outbreak among 128 thalassaemia outpatients followed at a thalassaemia centre of an Italian hospital. Methods: Epidemiological investigation and root-cause analysis were performed. All patients with acute hepatitis and known chronic infection were tested for HCV RNA, HCV genotyping, and NS3, NS5A, and NS5B HCV genomic region sequencing. To identify transmission clusters, phylogenetic trees were built for each…

SofosbuvirClinical risk management Hepatitis C virus (HCV) Molecular epidemiology Nosocomial outbreak Phylogenetic analysis Antiviral Agents Bayes Theorem Disease Outbreaks Genotype Hepacivirus Humans Italy Phylogeny Risk Management Hepatitis C ThalassemiaHepacivirusHepacivirus030501 epidemiologySettore MED/42 - Igiene Generale E Applicatamedicine.disease_causeDisease OutbreaksSettore MED/07chemistry.chemical_compoundSettore BIO/13 - Biologia ApplicataEpidemiologyMedicinePhylogenySettore MED/12 - Gastroenterologia0303 health sciencesClinical risk managementPhylogenetic analysisbiologyTransmission (medicine)virus diseasesGeneral MedicineHepatitis CHepatitis C virus (HCV)Hepatitis CInfectious DiseasesItalyMolecular epidemiologyThalassemia0305 other medical sciencemedicine.drugMicrobiology (medical)Ledipasvirmedicine.medical_specialtyGenotypeHepatitis C virusAntiviral Agents03 medical and health sciencesPhylogenetic analysiInternal medicineHumansRisk Management030306 microbiologybusiness.industryNosocomial outbreakBayes Theorembiology.organism_classificationmedicine.diseasedigestive system diseasesChronic infectionchemistrybusiness
researchProduct

Management and long-term follow-up of early stage H. pylori-associated gastric MALT-lymphoma in clinical practice: An Italian, multicentre study

2009

Abstract Background/Aim Data on management and long-term follow-up of Helicobacter pylori -associated MALT-lymphoma in clinical practice are scanty. We evaluate the long-term efficacy of H. pylori eradication on low-grade MALT-lymphoma, and the efficacy of further therapies in refractory patients. Methods This study enrolled patients with stages I–II 1 MALT-lymphoma and H. pylori infection. H. pylori eradication was attempted in all patients. Patients with lymphoma persistence or progression following H. pylori treatments received further lymphoma treatments. Both 5-year and disease-free survivals were calculated. Results Sixty patients (stage I/II 1 : 50/10) were followed up for a median t…

AdultMaleVincristinemedicine.medical_specialtyCyclophosphamideSettore MED/12 - GASTROENTEROLOGIAGastric maltomamanagementKaplan-Meier EstimateGastroenterologyDisease-Free SurvivalHelicobacter InfectionsYoung AdultStomach Neoplasmsimmune system diseasesPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansYoung adultCyclophosphamideAgedRetrospective StudiesAged 80 and overHelicobacter pyloriHepatologybiologybusiness.industryGastroenterologyProton Pump InhibitorsMALT lymphomaRetrospective cohort studyLymphoma B-Cell Marginal ZoneMiddle AgedHelicobacter pyloribiology.organism_classificationmedicine.diseaseAnti-Bacterial AgentsLymphomaSurgeryItalyDoxorubicinVincristinePrednisoneFemalebusinessFollow-Up Studiesmedicine.drug
researchProduct

Use of the word "cured" for cancer patients-implications for patients and physicians: the Siracusa charter

2015

Long-term survival for adult patients with solid tumours continues to increase. For some cancers, the possibility of recurrence after a number of years is extremely low, and the risk of death becomes similar to that of the general population of the same sex and age. During the Fifth European Conference on Survivors and Chronic Cancer Patients held in Siracusa, Italy, June 2014, oncologists, general practitioners, epidemiologists, cancer patients and survivors, and patient advocates joined to discuss the possible use of the term “cured” in reference to some adult patients with solid tumours. The specific focus was the appropriateness of using the term in communicating with cancer patients, s…

medicine.medical_specialtyPediatricsSettore MED/06 - Oncologia MedicaPopulationAlternative medicineMeeting ReportLong-term survivalLong-term survival; cure; implicationsmedicineElectronic communicationeducationPotential impacteducation.field_of_studybusiness.industryCharterCancermedicine.diseasecureimplicationsCure; Implications; Long-term survival; OncologyOncologyFamily medicineSame sexRisk of deathHuman medicinebusinessImplication
researchProduct

Analysis of Metabolic Parameters Coming from Basal and Interim PET in Hodgkin Lymphoma

2018

Objective: Positron Emission Tomography (PET) with F-18-Fluoro-deoxy-glucose (FDG) emerged as a prognostic tool to predict treatment outcome in Hodgkin Lymphoma (HL). Moreover, a FDG-PET adapted strategy is currently assessed in clinical trial to minimize the toxic effect while maintaining the efficacy of treatment in HL. Purpose was to analyze the quantitative parameters to support the prognostic role of FDG-PET today based on the semi-quantitative Deauville 5-point Scale (D5-PS). Methods: This retrospective study included 53 patients diagnosed with advanced-stage HL between 2009 and 2014, enrolled in the PET response-adapted clinical trial HD 0607. FDG-PET was performed at baseline (PET0)…

Pathologymedicine.medical_specialtyChemothrapy; FDG PET; Hodgkin lymphoma; Metabolic parameters; Metabolic tumor volume; Prognostic value; Radiology Nuclear Medicine and Imagingbusiness.industryHODGkin lymphomaMetabolic tumor volume02 engineering and technology021001 nanoscience & nanotechnologyInterim pet03 medical and health sciencesBasal (phylogenetics)0302 clinical medicineNuclear Medicine and ImagingFDG PETmedicineHodgkin lymphomaRadiology Nuclear Medicine and imaging030212 general & internal medicineMetabolic parametersRadiology0210 nano-technologyNuclear medicinebusinessPrognostic valueChemothrapyCurrent Medical Imaging Reviews
researchProduct